Last reviewed · How we verify
NCT05563389
Statin Impact on Hepatic Decompensation
Phase 2, PHASE3 trial testing Atorvastatin 20mg in Quality of Life in 100 participants. Completed in 25 February 2023.
25 February 2023
Quick facts
| Lead sponsor | Tanta University |
|---|---|
| Phase | Phase 2, PHASE3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 15 June 2022 |
| Primary completion | 25 February 2023 |
| Estimated completion | 25 February 2023 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Atorvastatin 20mg — full drug profile →
- Placebo
Conditions studied
- Quality of Life — all drugs for Quality of Life →
Sponsor
Tanta University
Who can join
Adults 18 to 75, any sex, with Quality of Life. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study aims to evaluate the impact of statin on hepatic decompensation.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Atorvastatin reduces recurrent decompensation events in advanced cirrhosis in a randomized placebo-controlled trial.
Glal KAM, El-Haggar SM, Abdel-Salam SM, Mostafa TM. · · 2026 · PMID 41865069 · DOI 10.1038/s41598-026-41326-4
Verify or expand the search:
- PubMed search for NCT05563389
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Atorvastatin 20mg
Trials testing the same drug.
- NCT06308952 — Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation · Phase 4 · recruiting
- NCT06248671 — Prophylactic Treatment With Atorvastatin for Episodic Migraine. · Phase 2 · recruiting
- NCT06327451 — Evaluate the Efficacy and Safety of Atorvastatin Combined With Temozolomide in the Treatment of Glioblastoma · Phase 2 · recruiting
- NCT06199921 — ATORvastatin in Pulmonary TUBerculosis · Phase 2 · recruiting
- NCT05049603 — A Randomized Clinical Trial to Evaluate the Effects of Atorvastatin on Graves' Orbitopathy (GO): the STAGO-2 Study · Phase 3 · not yet recruiting
Other recruiting trials for Quality of Life
Currently open trials in the same condition.
- NCT07498959 — Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer · NA · recruiting
- NCT07416448 — Neuroma-Associated Pain Management After Combat-Related Trauma in Ukraine · NA · recruiting
- NCT07412379 — Predictive Factors for Functional and Quality of Life Decline in Patients >65 Years With a Gastrointestinal Tract Cancer · recruiting
- NCT07380789 — Comprehensive Multicenter Study on the Management of Acute Pain Following Thoracic Combat-Related Trauma in Ukraine · NA · recruiting
- NCT07280416 — Evolution of Insomnia During the First Year in Patients Newly Diagnosed With Cancer · recruiting
Other Tanta University trials
Trials by the same sponsor.
- NCT07398651 — Apremilast and Adalimumab in Psoriatic Arthritis Patients · NA · not yet recruiting
- NCT06966856 — This Randomized, Clinical Trial Evaluates the Efficacy of Oral Versus Sublingual Vitamin B12 Supplementation in Correcti · Phase 3 · not yet recruiting
- NCT07334197 — Effect of Melatonin on Left Ventricular Reverse Remodeling and Inflammation in Peripartum Cardiomyopathy · NA · not yet recruiting
- NCT07498998 — Glucocorticoid, Ozone and 5% Dextrose Local Injection for Pain Relief in Carpal Tunnel Syndrome · NA · not yet recruiting
- NCT07114250 — Comparative Study Between Spinal Anesthesia Versus General Anesthesia in Supine Percutaneous Nephrolithotomy Operation · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05563389 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tanta University
- Last refreshed: 3 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05563389.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing